Does intravesical Bacillus Calmette-Guérin for bladder cancer protect from COVID-19?

IF 1.4 Q3 UROLOGY & NEPHROLOGY Archivio Italiano di Urologia e Andrologia Pub Date : 2024-05-09 DOI:10.4081/aiua.2024.12449

Anastasia MacDonald, Lexia Bao, Vahid Mehrnoush, Asmaa Ismail, Livio Di Matteo, Ahmed Zakaria, Hazem Elmansy, Peter Black, Ahmed Kotb

{"title":"Does intravesical Bacillus Calmette-Guérin for bladder cancer protect from COVID-19?","authors":"Anastasia MacDonald, Lexia Bao, Vahid Mehrnoush, Asmaa Ismail, Livio Di Matteo, Ahmed Zakaria, Hazem Elmansy, Peter Black, Ahmed Kotb","doi":"10.4081/aiua.2024.12449","DOIUrl":null,"url":null,"abstract":"Introduction: The study aimed to correlate the history of intravesical BCG as well as infantile BCG immunization with the incidence and severity of COVID-19 infection.Methods: Retrospective data collection of patients with high-risk non muscle invasive bladder cancer (NMIBC) from two Canadian centers. Data collection included a history of BCG instillation, infantile immunization, and the development of COVID-19 infection. Admission and/ or mortality because of COVID-19 was reported.Results: We could include data from 348 patients: including 188 and 160 patients from Ontario and British Columbia respectively. COVID-19 affected 15% of these patients. Intravesical BCG was used in 44% of these patients. Intravesical BCG and/or infantile BCG immunization did not correlate with the incidence of COVID-19 infection.Conclusions: Previous intravesical BCG and/ or a history of infantile BCG vaccination were not more/ less frequent in patients who had COVID-19 infection.","PeriodicalId":46900,"journal":{"name":"Archivio Italiano di Urologia e Andrologia","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivio Italiano di Urologia e Andrologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/aiua.2024.12449","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The study aimed to correlate the history of intravesical BCG as well as infantile BCG immunization with the incidence and severity of COVID-19 infection.

Methods: Retrospective data collection of patients with high-risk non muscle invasive bladder cancer (NMIBC) from two Canadian centers. Data collection included a history of BCG instillation, infantile immunization, and the development of COVID-19 infection. Admission and/ or mortality because of COVID-19 was reported.

Results: We could include data from 348 patients: including 188 and 160 patients from Ontario and British Columbia respectively. COVID-19 affected 15% of these patients. Intravesical BCG was used in 44% of these patients. Intravesical BCG and/or infantile BCG immunization did not correlate with the incidence of COVID-19 infection.

Conclusions: Previous intravesical BCG and/ or a history of infantile BCG vaccination were not more/ less frequent in patients who had COVID-19 infection.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

膀胱内卡介苗治疗膀胱癌能预防 COVID-19 吗？

导言该研究旨在将膀胱内卡介苗和婴儿卡介苗免疫史与 COVID-19 感染的发生率和严重程度联系起来：方法：对加拿大两个中心的高风险非肌层浸润性膀胱癌（NMIBC）患者进行回顾性数据收集。数据收集包括卡介苗灌注史、婴儿免疫接种史和 COVID-19 感染发展史。我们还报告了因感染 COVID-19 而入院和/或死亡的情况：我们可以纳入 348 名患者的数据：包括分别来自安大略省和不列颠哥伦比亚省的 188 名和 160 名患者。COVID-19感染了其中15%的患者。其中 44% 的患者使用了静脉内卡介苗。膀胱内卡介苗和/或婴儿卡介苗免疫与COVID-19感染的发生率无关：结论：曾接种过膀胱内卡介苗和/或婴儿卡介苗的患者在COVID-19感染中并不常见。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊